#214168

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

WILMINGTON, Del.--(BUSINESS WIRE)--Jun. 8, 2026-- Incyte (Nasdaq:INCY) announced today it has entered into a definitive agreement to acquire Vega Therapeutics, Inc., a wholly owned subsidiary of Star Therapeutics, LLC, for $1.25 billion. Star Therapeutics will be eligible to receive up to $750 million in additional payments upon the achievement of sales milestones...

By |2026-06-08T10:20:42-05:00June 8, 2026|Press Release|0 Comments
Read More

Star Therapeutics Receives FDA Rare Pediatric Disease and Breakthrough Therapy Designations for VGA039 in Von Willebrand Disease Prophylaxis

SOUTH SAN FRANCISCO, CA, April 21, 2026 – Star Therapeutics, a late clinical-stage biotechnology company focused on the discovery and development of life-changing therapies for diseases with significant unmet need, today announced that the U.S. Food and Drug Administration (FDA)...

By |2026-04-20T17:27:44-05:00April 21, 2026|Press Release|0 Comments
Read More

Star Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12

SOUTH SAN FRANCISCO, CA, January 5, 2026 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44th Annual...

By |2026-01-04T09:57:56-06:00January 5, 2026|Press Release|0 Comments
Read More

Star Therapeutics Presents Interim Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease, Demonstrating Substantial Bleed Reductions in All Patients, at ASH Annual Meeting

SOUTH SAN FRANCISCO, CA, December 6, 2025 – Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced interim data from its ongoing Phase 1/2 multidose...

By |2025-12-05T16:12:14-06:00December 6, 2025|Press Release|4 Comments
Read More

Star Therapeutics to Present Interim Data from Phase 1/2 Multidose Study of VGA039 in von Willebrand disease at ASH Annual Meeting

SOUTH SAN FRANCISCO, CA, November 3, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today...

By |2025-11-02T14:31:10-06:00November 3, 2025|Press Release|0 Comments
Read More

Star Therapeutics Announces Oversubscribed $125 Million Series D Financing

SOUTH SAN FRANCISCO, CA, September 30, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced an oversubscribed $125 million Series D financing.

By |2025-10-06T17:01:47-05:00September 30, 2025|Press Release|0 Comments
Read More

Star Therapeutics Receives FDA Fast Track Designation for VGA039 in Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, CA, January 6, 2025 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

By |2025-01-06T09:01:29-06:00January 6, 2025|Press Release|1 Comment
Read More

Star Therapeutics Presents Interim Clinical Data for VGA039 in Patients with Von Willebrand Disease (VWD) at ASH 2024

SOUTH SAN FRANCISCO, CA, December 9, 2024 – Star Therapeutics, a clinical stage biotechnology company.

By |2025-01-02T08:50:27-06:00December 9, 2024|Press Release|1 Comment
Read More

Star Therapeutics Presents Clinical Data for VGA039, a Subcutaneous Therapy for the Treatment of Von Willebrand Disease (VWD)

SOUTH SAN FRANCISCO, CA, June 26, 2024 – Star Therapeutics, a clinical stage biotechnology company discovering and developing best-in-class antibodies...

By |2024-06-26T11:43:52-05:00June 26, 2024|Press Release|0 Comments
Read More

THANK YOU

We look forward to connecting with you